177 related articles for article (PubMed ID: 31279302)
1. Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series.
Lemasson J; Cuzzubbo S; Doucet L; Gounant V; Baroudjian B; Herms F; Carpentier AF; Lebbé C; Vitaux H; Hautefort C; Delyon J;
Eur J Cancer; 2019 Aug; 117():116-118. PubMed ID: 31279302
[No Abstract] [Full Text] [Related]
2. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
3. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
4. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
5. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in cancer treatment and potential effect modification by age.
Eriksson H; Smedby KE
Acta Oncol; 2020 Mar; 59(3):247-248. PubMed ID: 32036733
[No Abstract] [Full Text] [Related]
7. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
8. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
Tomoaia R; Beyer RȘ; Pop D; Minciună IA; Dădârlat-Pop A
Eur J Cancer; 2020 Jun; 132():224-227. PubMed ID: 32336614
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
10. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
11. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Pan PC; Haggiagi A
Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
[TBL] [Abstract][Full Text] [Related]
12. Toxicities of checkpoint inhibitors: causes and management.
Postow MA
Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
[No Abstract] [Full Text] [Related]
13. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
[No Abstract] [Full Text] [Related]
14. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors.
Hui E
J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
[TBL] [Abstract][Full Text] [Related]
16. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
17. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
18. Management of Steroid-Refractory Immune-Related Adverse Events.
Watson ML; Beardslee T
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469899
[No Abstract] [Full Text] [Related]
19. Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
Brower V
Lancet Oncol; 2016 Dec; 17(12):e527. PubMed ID: 27866860
[No Abstract] [Full Text] [Related]
20. [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].
Gaultier De Saint Basile H; Poisson C; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Tartour E; De Guillebon E
Bull Cancer; 2018 Dec; 105(12):1202-1208. PubMed ID: 30471959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]